drugset
drugset / Trial / NCT01004250

A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer

NCT01004250 ↗

Phase 2 Completed 109 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

Participants with advanced non-small cell lung cancer (NSCLC) will receive a first-line treatment of Pemetrexed, Cisplatin and Bevacizumab as induction therapy followed by a maintenance treatment of Pemetrexed and Bevacizumab. Treatment will continue until disease progression or unacceptable toxicity occurs. The primary objective of this study is to measure how long this treatment could prevent the disease progression.

Timeline

Start
2009-10
Primary completion
2012-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma